TPCW
RYTM icon

TD Private Client Wealth’s Rhythm Pharmaceuticals RYTM Stock Holding History

TD Private Client Wealth’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$107 – 1725
2025
Q4 		$107 Buy
+1
New +$106 ﹤0.01% 1603

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

TD Private Client Wealth's RYTM Position: Q1 2026 in Review

TD Private Client Wealth sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 1 share — an estimated $107 sold.

TD Private Client Wealth first reported a position in RYTM in Q4 2025 and held it in 1 quarter. The position peaked at $107 in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • TD Private Client Wealth reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • TD Private Client Wealth sold 1 Rhythm Pharmaceuticals share in Q1 2026, an estimated $107.
  • TD Private Client Wealth first reported a position in Rhythm Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • TD Private Client Wealth's Rhythm Pharmaceuticals position peaked at $107 in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on TD Private Client Wealth's 13F filing for Q1 2026, filed 27 Apr 2026.